Introduction Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …

The advent of anti-HER2 cancer therapies has heralded significantly improved survival rates
along with decreased recurrence in breast cancer and is being increasingly used in other …

Opinion statement Human epidermal growth factor receptor 2-positive (HER2+) breast
cancer is associated with aggressive disease and a poor prognosis. There are a number of …

Due to the recent advances in diagnosis and management of patients with HER2-positive
breast cancer, especially through novel HER2-targeted agents, cardiotoxicity becomes an …

Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed
by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab …

Background Breast cancer is a leading cause of death for women worldwide, with incidence
increasing in lower-income countries. For patients with human epidermal growth factor …

Background Anti‐HER2 therapy‐related cardiotoxicity is well described in the context of
clinical trials, particularly in the setting of early stage disease, but there is more limited data …

Simple Summary Breast cancer is the most frequently diagnosed cancer in women, causing
over 500,000 deaths worldwide. Human epidermal growth factor receptor 2 is …

Purpose of Review HER2-targeted therapies have led to improved clinical outcomes in early
and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted …

Improved risk stratification of patients during HER2-targeted therapy and effective prevention
and management strategies for cardiotoxicity are needed to enhance the value of …